ArticleJournal of controlled release : official journal of the Controlled Release Society2020
Continuous in-line homogenization process for scale-up production of naltrexone-loaded PLGA microparticles.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 45 citations in OpenAlex.
- Systematic discovery of immunomodulatory plant-derived nanoparticles reveals RNA-mediated macrophage reprogramming.Bioactive materials · 2026Article
- Preparation of Uniform Nonspherical PLGA Particles in the Nanosize Range by Using a Two-Step Premix Membrane Emulsification Technique.ACS omega · 2026Article
- From bench to bulk: exploring in-line homogenization for scale-up and continuous production of vesicular systems.Drug delivery and translational research · 2026Article
- Preparation of Uniform PEG-PLLA Microspheres via Membrane Emulsification for Soft Tissue Filling Applications.Journal of functional biomaterials · 2026Article
- The Sr-HA-loaded PLGA cage structure combines cells to construct a bone tissue repair unit.Regenerative biomaterials · 2026Article
- Release mechanisms of PLGA microparticles prepared using a microfluidics device or a beaker.International journal of pharmaceutics: X · 2025Article
- Release mechanisms of PLGA-based drug delivery systems: A review.International journal of pharmaceutics: X · 2025Article
- Colistin and Oxyclozanide co-loaded PLGA nano-microspheres to reverse colistin resistance can effectively treat colistin-resistantInternational journal of pharmaceutics: X · 2025Article
- Long-Acting injectable buprenorphine PLGA microparticle formulation.International journal of pharmaceutics · 2025Article
- Process and Formulation Parameters Governing Polymeric Microparticle Formation via Sequential NanoPrecipitation (SNaP).ACS engineering Au · 2025Article
- Long-acting parenteral formulations of hydrophilic drugs, proteins, and peptide therapeutics: mechanisms, challenges, and therapeutic benefits with a focus on technologies.Drug delivery and translational research · 2025Review
- Development of Cyclodextrin-Based Mono and Dual Encapsulated Powders by Spray Drying for Successful Preservation of Everlasting Flower Extract.Pharmaceutics · 2024Article
- Polylactic Glycolic Acid-Mediated Delivery of Plectasin Derivative NZ2114 inAntibiotics (Basel, Switzerland) · 2024Article
- Polymer Delivery Systems for Long-Acting Antiretroviral Drugs.Pharmaceutics · 2024Review
- Trends on Novel Targets and Nanotechnology-Based Drug Delivery System in the Treatment of Parkinson's disease: Recent Advancement in Drug Development.Current drug targets · 2024Review
- The Impact of Post-Processing Temperature on PLGA Microparticle Properties.Pharmaceutical research · 2023Article
- Current and future directions of drug delivery for the treatment of mental illnesses.Advanced drug delivery reviews · 2023Review
- Transscleral Delivery of Dexamethasone-Loaded Microparticles Using a Dissolving Microneedle Array.Pharmaceutics · 2023Article
- The Management of Parkinson's Disease: An Overview of the Current Advancements in Drug Delivery Systems.Pharmaceutics · 2023Review
- Scanning Analysis of Sequential Semisolvent Vapor Impact To Study Naltrexone Release from Poly(lactide-co-glycolide) Microparticles.Molecular pharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
Abstract
Injectable, long-acting drug delivery systems provide effective drug concentrations in the blood for up to 6 months. Naltrexone-loaded poly(lactide-co-glycolide) (PLGA) microparticles were prepared using an in-line homogenization method. It allows the transition from a laboratory scale to scale-up production. This research was designed to understand how the processing parameters affect the properties of the microparticles, such as microparticle size distributions, surface and internal morphologies, drug loadings, and drug release kinetics, and thus, to control them. The in-line homogenization system was used at high flow rates for the oil- and water-phases, e.g., 100 mL/min and 400 mL/min, respectively, to continuously generate microparticles. A high molecular weight (148 kDa) PLGA at various concentrations was used to generate oil-phases with a range of viscosities and also to compare with a 64 and 79 kDa at a single, high concentration. The uniformity of the microparticles was found to be related to the viscosity of the oil-phase. As the viscosity of the oil-phase increased from 52.6 mPa∙s to 4046 mPa∙s, the span value (a measure of uniformity) increased from 1.24 to 3.1 for the microparticles generated at the homogenization speed of 2000 RPM. Increasing the PLGA concentration from 5.58% to 16.85% showed a corresponding rise in the encapsulation efficiency from 74.0% to 85.8% and drug loading (DL) from 27.4% to 31.7% for the microparticles made with the homogenization speed of 2000 RPM. These increases may be due to a faster shell formulation, enabling PLGA microparticles to entrap more naltrexone into the structure. A higher DL, however, shortened the drug release duration from 56 to 42 days. The changes in morphology of the microparticles during different phases of the in vitro release study were also studied for three types of microparticles made with different PLGA concentrations and molecular weights. As PLGA microparticles went through structural changes, the surface showed raisin-like wrinkled morphologies within the first 10 days. Then, the microparticles swelled to form smooth surfaces. The in-line approach produced PLGA microparticles with a highly reproducible size distribution, DL, and naltrexone release rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.